Does Blue Cross Blue Shield Cover Jardiance?

What Is Jardiance and Why Does Coverage Complexity Matter?

Jardiance (empagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three distinct indications, each of which can trigger different coverage rules under BCBS plans. Understanding which indication your prescriber is targeting directly affects whether prior authorization applies and what documentation your insurer will require.

The Three FDA-Approved Indications

The FDA first approved empagliflozin 10 mg and 25 mg in August 2014 for glycemic control in adults with type 2 diabetes (FDA drug label, NDA 204629). In August 2021, a supplemental approval extended use to reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status (FDA approval letter, sNDA 204629). A third approval followed in July 2023 for reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression (FDA labeling update).

Each new indication matters for BCBS coverage because plans may apply more stringent prior authorization criteria for the HFrEF and CKD indications, since those represent off-label-adjacent expansions that entered formularies more recently.

The Clinical Evidence Driving Prescriber Adoption

BCBS medical policies lean on the same landmark trials that drove FDA approval. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death and a 35% relative risk reduction in hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease treated with empagliflozin versus placebo (Zinman B et al., NEJM, 2015). The EMPEROR-Reduced trial (N=3,730) showed a 25% relative risk reduction in cardiovascular death or hospitalization for worsening heart failure (hazard ratio 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF with or without diabetes (Packer M et al., NEJM, 2020). The EMPA-KIDNEY trial (N=6,609) reported a 28% relative risk reduction in kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) (The EMPA-KIDNEY Collaborative Group, NEJM, 2023).

These data sit behind the American Diabetes Association's 2024 Standards of Care, which assign Jardiance a Grade A recommendation for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, and similarly endorse SGLT2 inhibitors for CKD with albuminuria (American Diabetes Association, Diabetes Care, 2024). Insurers including BCBS affiliates use these guidelines when writing medical necessity criteria.

How BCBS Formularies Place Jardiance

Most Blue Cross Blue Shield commercial formularies place Jardiance on Tier 3, the preferred brand tier. That tier position is meaningful: Tier 3 copays typically run $50, $100 per 30-day supply under standard commercial plans, while Tier 4 or non-preferred brand placements can push cost-sharing to $150, $300 or higher before deductible is met.

Commercial vs. Medicare vs. Medicaid Plans

BCBS operates through 34 independent licensee companies across the United States. This means formulary placement for Jardiance is not uniform. Here is how the three major plan types generally handle coverage:

Commercial (employer-sponsored and marketplace) plans. Jardiance appears on most BCBS commercial formularies at Tier 3. Patients with an unmet deductible pay full negotiated cost until the deductible clears, then the Tier 3 copay or coinsurance applies. The Jardiance Savings Card from Boehringer Ingelheim can reduce commercial patient cost-sharing to as low as $10 per month for eligible patients (Boehringer Ingelheim patient savings program).

Medicare Part D plans. Federal anti-kickback rules mean the manufacturer savings card cannot be used with Medicare. BCBS Medicare Part D plan formularies vary by region. Jardiance has appeared on formulary for multiple BCBS Medicare plans, often in the higher Tier 3 or Tier 4 position. The Medicare Prescription Payment Plan (previously Extra Help) and the redesigned $2,000 out-of-pocket cap starting in 2025 under the Inflation Reduction Act may meaningfully reduce annual cost for Medicare beneficiaries. Patients should use the Medicare Plan Finder at CMS to check their specific BCBS Part D plan (CMS Medicare Plan Finder).

Medicaid managed care plans. State Medicaid programs that contract with BCBS affiliates (for example, Anthem Blue Cross in California Medicaid) set formularies at the state level. Many state Medicaid programs do cover Jardiance for type 2 diabetes under preferred diabetic agent criteria, but prior authorization requirements tend to be stricter than commercial plans. Coverage for the HFrEF and CKD indications on Medicaid is less consistent.

Step Therapy Requirements

Several BCBS affiliates require step therapy before covering Jardiance. Step therapy means the plan requires documentation that a patient has already tried and either failed, could not tolerate, or has a contraindication to a first-line agent, usually metformin. The 2022 ADA Standards note that metformin remains a cost-effective first-line agent for most patients with type 2 diabetes without compelling cardiovascular or renal indications (ADA Standards of Medical Care in Diabetes, 2022). If your BCBS plan imposes step therapy, your prescriber will need to document that metformin was tried or is contraindicated.

Prior Authorization for Jardiance Under BCBS Plans

Prior authorization (PA) is required by many BCBS affiliates for Jardiance, regardless of indication. The PA process asks your prescriber to submit clinical documentation justifying medical necessity.

What Triggers a PA Request

PA is most consistently required in these situations:

• Prescribing Jardiance for HFrEF without a concurrent diabetes diagnosis
• Prescribing for CKD in patients with eGFR below 30 mL/min/1.73 m2 (some plans restrict use below this threshold)
• First-time fills for Jardiance on plans with step-therapy requirements
• Patients on Medicare Part D with certain low-income subsidy designations

What Documentation Supports Approval

A strong PA submission for Jardiance typically includes the following:

• Recent HbA1c values (for type 2 diabetes indication)
• Echocardiogram confirming reduced ejection fraction at or below 40% (for HFrEF indication)
• Recent urine albumin-to-creatinine ratio (UACR) and eGFR for CKD indication
• A statement of contraindication or intolerance to alternatives if step therapy applies
• Documentation of current cardiovascular risk factors or confirmed atherosclerotic cardiovascular disease

The 2022 AHA/ACC/HFSA Heart Failure Guidelines give a Class I, Level of Evidence A recommendation to SGLT2 inhibitors for patients with HFrEF to reduce cardiovascular mortality and heart failure hospitalizations (Heidenreich PA et al., JACC, 2022). Including this citation in a PA appeal letter can support the prescriber's argument.

PA Timelines

Standard PA requests must receive a decision within 3 business days under most state laws. Urgent or expedited PA requests must be resolved within 24 to 72 hours. If your prescriber's office submits a PA and it is approved, coverage usually applies immediately or on the next fill. If denied, you move to the appeals process.

What Happens When BCBS Denies Coverage for Jardiance

A denial is not a final answer. The appeals process exists specifically for situations where a plan's initial coverage decision conflicts with your clinical picture.

Levels of Appeal

Most BCBS plans follow a two-level internal appeal process before offering an external independent review:

1. First-level internal appeal: Submit within 180 days of the denial notice. Your prescriber writes a letter citing the specific clinical evidence and the relevant FDA-approved indication.
2. Second-level internal appeal: If the first appeal fails, a different medical reviewer at BCBS examines the case.
3. External independent review: Required by law in all states under the ACA if both internal appeals fail. An independent organization, not affiliated with BCBS, makes a binding decision.

Leveraging Clinical Guidelines in Appeals

Appeals succeed more often when they cite specific published guidelines. The 2023 KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease recommends SGLT2 inhibitors for patients with type 2 diabetes and CKD when eGFR is 20 mL/min/1.73 m2 or higher (KDIGO 2022 Clinical Practice Guideline, Kidney International Supplements). A PA appeal citing KDIGO 2022, the EMPA-KIDNEY trial results, and the FDA label simultaneously gives the reviewing clinician at BCBS clear grounds for approval.

Cost Without Coverage and Available Assistance Programs

If coverage is denied and appeals are exhausted, or while waiting for PA approval, patients have several cost-reduction options.

Manufacturer Savings Card

Boehringer Ingelheim and Eli Lilly offer a Jardiance Savings Card that reduces cost-sharing to as low as $10 per 30-day supply for commercially insured eligible patients. The maximum savings is $150 per fill. The card is available at jardiance.com and does not require income verification for commercially insured patients. It cannot be used with Medicare, Medicaid, or any government-funded insurance.

GoodRx and Cash-Pay Pricing

GoodRx and similar discount programs offer Jardiance at negotiated cash prices that typically range from $450 to $570 per 30-day supply at major pharmacy chains, compared to the list price of approximately $680. These prices vary by pharmacy and ZIP code. Using a GoodRx coupon voids insurance coverage for that fill, so patients should confirm which approach is cheaper after applying their specific BCBS copay.

Patient Assistance Program

Boehringer Ingelheim's patient assistance program, the Boehringer Ingelheim Cares Foundation, provides Jardiance at no cost to uninsured or underinsured patients who meet income eligibility requirements (generally at or below 400% of the federal poverty level). Prescribers can initiate an application at boehringer-ingelheim.com.

Alternatives BCBS May Prefer Over Jardiance

If Jardiance faces non-formulary status or consistent PA denials on your specific BCBS plan, your prescriber may consider therapeutically similar SGLT2 inhibitors that carry more favorable tier placement.

Other SGLT2 Inhibitors on BCBS Formularies

Farxiga (dapagliflozin) holds FDA approvals for type 2 diabetes, HFrEF, heart failure with preserved ejection fraction (HFpEF), and CKD. The DAPA-HF trial (N=4,744) showed a 26% relative risk reduction in cardiovascular death or worsening heart failure events (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) with dapagliflozin in HFrEF patients (McMurray JJV et al., NEJM, 2019). Some BCBS plans place dapagliflozin at Tier 3 alongside empagliflozin; others prefer one over the other.

Invokana (canagliflozin) is FDA-approved for type 2 diabetes and for reducing end-stage kidney disease and cardiovascular events in patients with type 2 diabetes and diabetic nephropathy. The CREDENCE trial (N=4,401) demonstrated a 30% relative risk reduction in the primary composite renal endpoint (HR 0.70, 95% CI 0.59 to 0.82, P<0.001) (Perkovic V et al., NEJM, 2019).

Switching to a formulary-preferred alternative is a legitimate clinical strategy when the therapeutic profiles are similar and the patient does not have a specific reason to prefer one agent. Your prescriber and your BCBS plan's clinical pharmacist can help assess this.

A Decision Framework for Navigating BCBS Jardiance Coverage

The pathway below organizes the coverage process into discrete steps so patients and prescribers can work through coverage systematically rather than reacting to each denial independently.

Step 1: Confirm Your Plan's Formulary Status Before the First Fill

Call the member services number on your BCBS insurance card or log in to your plan's online portal and search the drug formulary for "empagliflozin" or "Jardiance." Note the tier, any step-therapy requirements, and whether PA is flagged. This takes 10 minutes and prevents a surprise bill at the pharmacy.

Step 2: Identify the Correct Indication for Your PA Submission

Your prescriber should submit the PA under the FDA-approved indication that best matches your clinical picture. Submitting under type 2 diabetes when the primary rationale is HFrEF, or vice versa, can result in an unnecessary denial. Each indication has different supporting documentation requirements.

Step 3: Submit PA with Full Clinical Documentation on Day One

Do not wait for a PA denial before gathering supporting labs. Submitting a complete PA on the first attempt, including HbA1c, echocardiography results, UACR, eGFR, and relevant guideline citations, reduces the likelihood of denial and shortens overall time to approval.

Step 4: Use the Savings Card or Patient Assistance During the PA Window

If the PA is pending and you need to start treatment, a 30-day supply purchased with the Jardiance Savings Card (for commercially insured patients) or through the patient assistance program can bridge the gap while the coverage decision is finalized.

Step 5: Appeal With Guideline Citations if Denied

An appeal letter that references the EMPA-REG OUTCOME, EMPEROR-Reduced, or EMPA-KIDNEY trial by name, cites the ADA 2024 Standards of Care, and quotes the relevant guideline recommendation grade stands a meaningfully stronger chance of reversal than a generic letter of medical necessity.

How Much Does Jardiance Cost With BCBS Coverage?

Actual out-of-pocket cost depends on your specific BCBS plan's tier structure, deductible status, and whether you qualify for the manufacturer savings card.

Estimated Monthly Cost Ranges

| Coverage Situation | Estimated Monthly Out-of-Pocket | |---|---| | BCBS commercial, Tier 3 copay, deductible met | $50, $100 | | BCBS commercial, Tier 3 copay + Savings Card | As low as $10 | | BCBS commercial, deductible not met (pre-deductible) | $450, $600 (negotiated rate) | | BCBS Medicare Part D, Tier 3, 2025 cap applies | Variable; maximum $2,000 annually | | Uninsured, cash pay with GoodRx | $450, $570 | | Patient assistance program (income-eligible) | $0 |

These ranges reflect 2025 pricing estimates and will shift with annual formulary updates each January 1. Patients should re-verify coverage at each open enrollment period.

What Your Prescriber Can Do to Improve Coverage Odds

Prescribers play the largest single role in determining whether a patient gets Jardiance covered. Specific actions that improve success rates include:

Submitting PA on the same day as the prescription rather than waiting for a pharmacy-initiated rejection. Ensuring the ICD-10 diagnosis code on the PA matches the FDA-approved indication being requested (E11.65 for type 2 diabetes with hyperglycemia, I50.20 for unspecified heart failure, N18.3, N18.5 for CKD stages). Including the full clinical rationale with supporting labs rather than a single-line "medically necessary" statement. Following up within 72 hours if no decision has been issued.

The American Diabetes Association notes that "patient and provider advocacy, appeals processes, and step therapy override laws are underutilized tools that can substantially reduce drug cost barriers" (ADA Standards of Medical Care in Diabetes, 2024).

Does BCBS Cover Jardiance for Heart Failure Without Diabetes?

Yes, many BCBS commercial plans cover Jardiance for HFrEF even when the patient does not have type 2 diabetes. This follows the FDA's 2021 approval for HFrEF regardless of glycemic status. Coverage for HFpEF under this indication is not supported by the current Jardiance label; Farxiga (dapagliflozin) holds the HFpEF approval based on the EMPEROR-Preserved trial (N=5,988), which showed a 21% relative risk reduction in cardiovascular death or hospitalization for worsening heart failure (HR 0.79, 95% CI 0.69 to 0.90, P<0.001) (Anker SD et al., NEJM, 2021).

For non-diabetic HFrEF patients seeking Jardiance coverage under BCBS, the PA submission should lead with the 2022 AHA/ACC/HFSA guideline Class I recommendation and include the echocardiogram confirming EF at or below 40%.

Does BCBS Cover Jardiance for Chronic Kidney Disease?

Coverage for the CKD indication is available under many BCBS plans following the July 2023 FDA approval, but PA requirements are more consistently applied here than for the diabetes indication. The KDIGO 2022 guideline recommends SGLT2 inhibitors for patients with CKD and eGFR of 20 mL/min/1.73 m2 or higher, and this recommendation carries a Grade 1A level of evidence (KDIGO 2022, Kidney International Supplements). Including the eGFR value, UACR, and the KDIGO guideline recommendation in the PA documentation is the single most effective step for CKD-indication PA submissions.